Literature DB >> 26156055

Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells.

Gianluca Marucci1, Dario de Biase2, Matteo Zoli3, Marco Faustini-Fustini4, Antonella Bacci5, Ernesto Pasquini6, Michela Visani7, Diego Mazzatenta3, Giorgio Frank3, Giovanni Tallini2.   

Abstract

PURPOSE: To assess the role of high sensitivity next-generation sequencing (NGS) of CTNNB1 for the diagnosis of adamantinomatous craniopharyngiomas (aCPs) and of BRAF for that of papillary CPs (pCPs) in routinely processed surgical samples of non-adenomatous sellar lesions.
METHODS: Forty-five cases of patients operated for non-adenomatous masses of the sellar region between 2004 and 2014 were retrieved from the files of the Anatomic Pathology unit of the Bellaria Hospital in Bologna, Italy. BRAF and CTNNB1 mutation status was analyzed by NGS in samples smaller than 1 cm(3) and histological re-evaluation was performed on all cases.
RESULTS: CTNNB1 mutation analysis showed a sensitivity of 86.7 % and a specificity of 96.2 % for the diagnosis of aCPs. The specificity increased to 100 % considering that in one case, initially classified as a non-CP lesion (xanthogranuloma), the identification of a CTNNB1 S47R lead to histological re-evaluation and reclassification of the lesion as aCP. BRAF mutation analysis had a sensitivity of 76.9 % and a specificity of 96.4 % for the diagnosis of pCPs. The specificity increased to 100 % considering that in one case, initially classified as a Rathke cyst, the identification of BRAF V600E lead to histological re-evaluation and reclassification of the lesion as pCP.
CONCLUSIONS: This study confirms the diagnostic relevance of the molecular alterations recently identified in aCPs and pCPs and shows how the identification of BRAF and CTNNB1 mutations can be instrumental for the proper classification of samples that contain limiting amounts of diagnostic lesional tissue.

Entities:  

Keywords:  Adamantinomatous craniopharyngioma; BRAF; Beta-catenin; CTNNB1; Papillary craniopharyngioma; Rathke cleft cyst

Mesh:

Substances:

Year:  2015        PMID: 26156055     DOI: 10.1007/s11102-015-0669-y

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  19 in total

1.  Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations.

Authors:  Shigeki Sekine; Tatsuhiro Shibata; Akiko Kokubu; Yukio Morishita; Masayuki Noguchi; Yukihiro Nakanishi; Michiie Sakamoto; Setsuo Hirohashi
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 2.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

3.  The endoscopic endonasal approach for the management of craniopharyngiomas: a series of 103 patients.

Authors:  Luigi Maria Cavallo; Giorgio Frank; Paolo Cappabianca; Domenico Solari; Diego Mazzatenta; Alessandro Villa; Matteo Zoli; Alfonso Iodice D'Enza; Felice Esposito; Ernesto Pasquini
Journal:  J Neurosurg       Date:  2014-05-02       Impact factor: 5.115

4.  Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region.

Authors:  Rolf Buslei; Michael Nolde; Bernd Hofmann; Stephan Meissner; Ilker Y Eyupoglu; Florian Siebzehnrübl; Eric Hahnen; Jürgen Kreutzer; Rudolf Fahlbusch
Journal:  Acta Neuropathol       Date:  2005-05-13       Impact factor: 17.088

5.  Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia.

Authors:  Robert T Jones; Malak S Abedalthagafi; Mohan Brahmandam; Edward A Greenfield; Mai P Hoang; David N Louis; Jason L Hornick; Sandro Santagata
Journal:  Mod Pathol       Date:  2014-11-21       Impact factor: 7.842

6.  Nuclear beta-catenin accumulation as reliable marker for the differentiation between cystic craniopharyngiomas and rathke cleft cysts: a clinico-pathologic approach.

Authors:  Bernd M Hofmann; Jürgen Kreutzer; Wolfgang Saeger; Michael Buchfelder; Ingmar Blümcke; Rudolf Fahlbusch; Rolf Buslei
Journal:  Am J Surg Pathol       Date:  2006-12       Impact factor: 6.394

7.  The spectrum of malignancy in craniopharyngioma.

Authors:  Fausto J Rodriguez; Bernd W Scheithauer; Shigeru Tsunoda; Kalman Kovacs; Sergio Vidal; David G Piepgras
Journal:  Am J Surg Pathol       Date:  2007-07       Impact factor: 6.394

8.  Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.

Authors:  Priscilla K Brastianos; Amaro Taylor-Weiner; Peter E Manley; Robert T Jones; Dora Dias-Santagata; Aaron R Thorner; Michael S Lawrence; Fausto J Rodriguez; Lindsay A Bernardo; Laura Schubert; Ashwini Sunkavalli; Nick Shillingford; Monica L Calicchio; Hart G W Lidov; Hala Taha; Maria Martinez-Lage; Mariarita Santi; Phillip B Storm; John Y K Lee; James N Palmer; Nithin D Adappa; R Michael Scott; Ian F Dunn; Edward R Laws; Chip Stewart; Keith L Ligon; Mai P Hoang; Paul Van Hummelen; William C Hahn; David N Louis; Adam C Resnick; Mark W Kieran; Gad Getz; Sandro Santagata
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 38.330

9.  Mutant BRAF in low-grade epilepsy-associated tumors and focal cortical dysplasia.

Authors:  Gianluca Marucci; Dario de Biase; Michela Visani; Marco Giulioni; Matteo Martinoni; Llilia Volpi; Patrizia Riguzzi; Guido Rubboli; Roberto Michelucci; Giovanni Tallini
Journal:  Ann Clin Transl Neurol       Date:  2014-01-09       Impact factor: 4.511

10.  Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens.

Authors:  Inger Marie Løes; Heike Immervoll; Jon-Helge Angelsen; Arild Horn; Jürgen Geisler; Christian Busch; Per Eystein Lønning; Stian Knappskog
Journal:  Tumour Biol       Date:  2014-10-16
View more
  12 in total

Review 1.  Can tissue biomarkers reliably predict the biological behavior of craniopharyngiomas? A comprehensive overview.

Authors:  Ruth Prieto; José M Pascual
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

Review 2.  The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.

Authors:  Craig Horbinski; Keith L Ligon; Priscilla Brastianos; Jason T Huse; Monica Venere; Susan Chang; Jan Buckner; Timothy Cloughesy; Robert B Jenkins; Caterina Giannini; Roger Stupp; L Burt Nabors; Patrick Y Wen; Kenneth J Aldape; Rimas V Lukas; Evanthia Galanis; Charles G Eberhart; Daniel J Brat; Jann N Sarkaria
Journal:  Neuro Oncol       Date:  2019-12-17       Impact factor: 12.300

3.  Distinct patterns of primary and motile cilia in Rathke's cleft cysts and craniopharyngioma subtypes.

Authors:  Shannon Coy; Ziming Du; Shu-Hsien Sheu; Terri Woo; Fausto J Rodriguez; Mark W Kieran; Sandro Santagata
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

4.  Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?

Authors:  Noriaki Fukuhara; Takeo Iwata; Naoko Inoshita; Katsuhiko Yoshimoto; Masanobu Kitagawa; Hirokazu Fukuhara; Keita Tatsushima; Mitsuo Yamaguchi-Okada; Akira Takeshita; Junko Ito; Yasuhiro Takeuchi; Shozo Yamada; Hiroshi Nishioka
Journal:  Endocr Pathol       Date:  2020-09-23       Impact factor: 3.943

5.  BRAF V600E mutant papillary craniopharyngiomas: a single-institutional case series.

Authors:  Emanuele La Corte; Iyan Younus; Francesca Pivari; Adelina Selimi; Malte Ottenhausen; Jonathan A Forbes; David J Pisapia; Georgiana A Dobri; Vijay K Anand; Theodore H Schwartz
Journal:  Pituitary       Date:  2018-12       Impact factor: 4.107

6.  Rathke's Cleft Cyst as Origin of a Pediatric Papillary Craniopharyngioma.

Authors:  Sven-Martin Schlaffer; Michael Buchfelder; Robert Stoehr; Rolf Buslei; Annett Hölsken
Journal:  Front Genet       Date:  2018-02-22       Impact factor: 4.599

7.  Molecular Diagnostic of Solid Tumor Using a Next Generation Sequencing Custom-Designed Multi-Gene Panel.

Authors:  Dario de Biase; Giorgia Acquaviva; Michela Visani; Viviana Sanza; Chiara M Argento; Antonio De Leo; Thais Maloberti; Annalisa Pession; Giovanni Tallini
Journal:  Diagnostics (Basel)       Date:  2020-04-23

8.  Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature.

Authors:  R Borrill; E Cheesman; S Stivaros; I D Kamaly-Asl; K Gnanalingham; John-Paul Kilday
Journal:  Childs Nerv Syst       Date:  2018-08-01       Impact factor: 1.475

9.  Adamantinomatous Craniopharyngioma in an Adult: A Case Report with NGS Analysis.

Authors:  Raid A Jastania; Muhammad Saeed; Hisham Al-Khalidi; Khalid AlQuthami; Tahani H Nageeti; Faisal A Al-Allaf; Kristoffer Valerie; Mohiuddin M Taher
Journal:  Int Med Case Rep J       Date:  2020-04-21

10.  Genetic and immune profiling for potential therapeutic targets in adult human craniopharyngioma.

Authors:  Cynthia Kassab; Daniel Zamler; Carlos Kamiya-Matsuoka; Zoran Gatalica; Joanne Xiu; David Spetzler; Amy B Heimberger
Journal:  Clin Oncol Res       Date:  2019-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.